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Stroke is a leading cause of death and disability in the United States. The lack of clinical
success in stroke therapies can be attributed, in part, to inadequate basic research on
aging rodents. The current study demonstrates that recombinant TCR ligand therapy uses
different immunological mechanisms to protect young and older mice from experimental
stroke. In young mice, RTL1000 therapy inhibited splenocyte efflux while reducing
frequency of T cells and macrophages in the spleen. Older mice treated with RTL1000
exhibited a significant reduction in inflammatory cells in the brain and inhibition of splenic
atrophy. Our data suggest age specific differences in immune response to stroke that
allow unique targeting of stroke immunotherapies.
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INTRODUCTION
Stroke is a leading cause of death and disability in the United
States. It is now increasingly evident that the immune response
plays an important role in neurodegeneration following stroke.
Splenic activation after stroke leads to an efflux of immune
cells into the blood that subsequently target the brain, acti-
vate microglial cells and exacerbate the evolving brain infarct
(Offner et al., 2006a,b; Seifert et al., 2012a,b). T cells are thought
to be among the major contributors in post-ischemic immune
response. T cells infiltrate the brain, perpetuate inflammatory
conditions and contribute to increased neuronal damage fol-
lowing stroke (Shichita et al., 2009; Gronberg et al., 2013).
Additionally, T cell knockout mice exhibit reduced infarct volume
(Yilmaz et al., 2006).
Given their significant involvement in the pathogenesis of
stroke, T cells are a crucial target for stroke therapy. Recombinant
T-cell receptor ligand (RTL) molecules consist of the α1 and
β1 domains of MHC class II molecules expressed as a single
polypeptide with or without antigenic amino terminal exten-
sions (Burrows et al., 1999; Vandenbark et al., 2003). RTLs are
partial agonists that deviate autoreactive T cells to become non-
pathogenic (Burrows et al., 2001; Wang et al., 2003). Previous
Abbreviations: RTL, recombinant T-cell receptor ligand; MCAO, middle cerebral
artery occlusion; Treg, regulatory T cell; MHC,Major Histocompatibility Complex;
HLA, Human leukocyte antigen; MOG, myelin oligodendrocyte glycoprotein; LDF,
Laser Doppler flowmetry; PHA, Phytohemagglutinin; PMA, Phorbol myristate
acetate.
work done by our lab has shown that RTL could treat both exper-
imental autoimmune encephalomyelitis (EAE) and experimental
stroke in mice (Burrows et al., 1998, 2001; Vandenbark et al.,
2003; Huan et al., 2004; Subramanian et al., 2009; Akiyoshi et al.,
2011; Dziennis et al., 2011; Benedek et al., 2014). RTL1000 is
comprised of an HLA-DR2 moiety linked to human MOG-35-
55 peptide (Offner et al., 2011) and has been shown to reduce
infarct size when young humanized DR2 mice were treated fol-
lowing experimental stroke (Akiyoshi et al., 2011; Pan et al., 2014;
Zhu et al., 2014).
With the potential success of RTL as a stroke therapy it
becomes imperative to not only characterize the effects of RTL
on the inflammatory response following stroke but to also test
the RTL therapy in older mice during experimental stroke. The
increased risk for stroke with age along with the substantially
growing aging population will lead to an additional 3.4 million
people affected by stroke by the year 2030 compared to 2012
(Ovbiagele et al., 2013). Despite the unavoidable and increasing
financial burden of post-stroke care, many experimental stroke
therapies have been abandoned due to their failure in the clinical
setting (O’Collins et al., 2006). The inability of stroke therapy to
be translated from bench to clinical success can be attributed, in
part, to the lack of aging rodents used in basic research (Liu and
McCullough, 2011). By examining the effects of RTL therapy on
experimental stroke in both young and older mice we can more
accurately determine the mechanism of therapy and predict its
translation to clinical use.
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MATERIALS AND METHODS
ETHICS STATEMENT
The study was conducted in accordance with National Institutes
of Health guidelines for the use of experimental animals, and the
protocols were approved by Animal Care and Use Committee at
Oregon Health & Science University and the Portland Veteran
Affairs Medical Center.
ANIMALS
All experiments used age-matched, sexually mature (20–25 g)
male HLA-DRB1∗1502 (DR2-Tg) mice produced by Dr. Chella
David (Gonzalez-Gay et al., 1996). The mice were housed and
bred at the Veterans Affairs Medical Center and studies were
conducted at Oregon Health and Science University.
RTL1000 CONSTRUCTION AND PRODUCTION
RTL molecules consist of the α1 and β1 domains of major histo-
compatibility complex (MHC) II molecules and are expressed as
a single polypeptide with or without antigenic amino terminal
extensions (Burrows et al., 1999). RTL1000 (β1α1[5D substi-
tuted] domains of HLA-DR2 linked to human [h]MOG-35-55
peptide [MEVGWYRPPFSRVVHLYRNGK]) was constructed de
novo or by sequential site-directed mutagenesis of previous con-
structs (Sinha et al., 2007). Protein purification was carried out as
previously described (Burrows et al., 1999).
TREATMENT WITH RTL1000
Mice were randomized to receive 0.1mL (100μg) RTL1000 or
0.1mL vehicle (5% dextrose in Tris-HCl, pH 8.5) by subcuta-
neous injection 4 h after the onset of reperfusion followed by
doses at 24, 48, and 72 h of reperfusion for a total of four treat-
ments each of RTL1000 or Vehicle. Both RTL1000 and vehicle
treated mice were euthanized at the 96 h time-point after MCAO
for further examination of tissues and cells.
TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION
Transient focal cerebral ischemia was induced in male DR2-Tg
mice for 1 h by reversible right MCAO under isoflurane anes-
thesia followed by 96 h of reperfusion as described previously
(Zhang et al., 2008). Head and body temperature were controlled
at 36.5± 0.5◦C throughoutMCAO surgery with warmwater pads
and a heating lamp. Occlusion and reperfusion were verified in
each animal by laser Doppler flowmetry (LDF) (Model DRT4,
Moor Instruments Ltd., Oxford, England). The common carotid
artery was exposed and the external carotid artery was ligated
and cauterized. Unilateral MCAO was accomplished by insert-
ing a 6-0 nylon monofilament surgical suture (ETHICON, Inc.,
Somerville, NJ, USA) with a heat-rounded and silicone-coated
(Xantopren comfort light, Heraeus, Germany) tip into the inter-
nal carotid artery via the external carotid artery stump. Adequacy
of MCAO was confirmed by monitoring cortical blood flow at
the onset of the occlusion with a LDF probe affixed to the skull.
Animals were excluded if mean intra-ischemic LDF was greater
than 30%pre-ischemic baseline. At 1 h of occlusion, the occluding
filament was withdrawn to allow for reperfusion. Mice were then
allowed to recover from anesthesia and survived for 96 h following
initiation of reperfusion.
DETERMINATION OF INFARCT SIZE
The brains were harvested after 96 h of reperfusion and sliced
into four 2-mm-thick coronal sections for staining with 1.2%
2,3,5-triphenyltetrazolium chloride (TTC; Sigma, St. Louis, MO,
USA) in saline as described previously (Hurn et al., 2007). The
2-mm brain sections were incubated in 1.2% TTC for 15min at
37◦C, and then fixed in 10% formalin for 24 h. Infarction volume
was measured using digital imaging and image analysis software
(Systat, Inc., Point Richmond, CA, USA). To control for edema,
infarct volume (cortex, striatum, and hemisphere) was deter-
mined by subtraction of the ipsilateral non-infarcted regional
volume from the contralateral regional volume. This value was
then divided by the contralateral regional volume and multiplied
by 100 to yield regional infarction volume as a percent of the
contralateral region.
LEUKOCYTE ISOLATION FROM BRAIN AND SPLEEN
Spleens from individual MCAO-treated mice were removed and a
single-cell suspension was prepared by passing the tissue through
a 100μm nylon mesh (BD Falcon, Bedford, MA). The cells were
washed using RPMI 1640 and the red blood cells lysed using
1× red blood cell lysis buffer (eBioscience, Inc., San Diego, CA)
and incubated for 1min. The cells were then washed with RPMI
1640, counted on a Cellometer Auto T4 cell counter (Nexcelom,
Lawrence, MA), and resuspended in staining medium [PBS con-
taining 0.1% NaN3 and 1% bovine serum albumin (Sigma, IL)]
for flow cytometry. The brain was divided into the ischemic
(right) and non-ischemic (left) hemispheres, digested for 60min
with 1mg/ml Type IV collagenase (Sigma Aldrich, St. Louis, MO)
and DNase I (50mg/ml, Roche Diagnostics, Indianapolis, IN) at
37◦C with intermittent shaking. Samples were mixed with a 1ml
pipette every 15min. The suspension was washed 1× in RPMI,
resuspended in 80% Percoll overlayed with 40% Percoll, and cen-
trifuged for 30min at 1600 RPM. The cells were then washed
twice with RPMI 1640 and resuspended in staining medium for
flow cytometry.
ANALYSIS OF CELL POPULATIONS BY FLOW CYTOMETRY
All antibodies were purchased (BD Biosciences, San Jose, CA
or eBioscience, Inc., San Diego, CA) as published. Four-color
(FITC, PE, APC, and PerCP) fluorescence flow cytometry anal-
yses were performed to determine the phenotypes of spleno-
cytes and brain cells. One million cells were washed with
staining medium, blocked with Anti-mouse CD16/CD32 Mouse
BD Fc Block™ (BD Biosciences, San Jose) for 15min at 4◦C
and then incubated with combinations of the following mon-
oclonal antibodies: CD11b (MAC-1), CD45 (Ly-5), CD3 (145-
2C11), CD11c (HL-3), CD19 (1D3), CD4 (GK1.5), CD8 (53-
6.7), Ly6C (AL-21), Ly6G (RB6-8C5), CD122 (TM-β1), CD44
(IM7), CCR5 (HM-CCR5), and CD69 (H1.2F3) for 20min at
4◦C. 7-AAD was added to identify dead cells. CD4+ regulatory
T cells were identified using Foxp3 (FJK-16s) and accompa-
nying Fixation/Permeabilization reagents as per manufacturer’s
instructions (eBioscience, Inc., San Diego, CA). Isotype matched
mAb served as a negative control. Data were collected with BD
Accuri™ C6 software on a BD Accuri™ C6 (BD Biosciences, San
Jose, CA).
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CYTOKINE DETERMINATION BY INTRACELLULAR CYTOKINE FLOW
CYTOMETRY ANALYSIS
Splenocytes from individual mice were cultured at 2 × 106
cells/well in a 24-well culture plate in stimulation medium
(RPMI, 1% sodium pyruvate, 1% L-glutamine, 0.4% 2-β-
mercaptoethanol, 2% FBS) with PMA (50 ng/ml), ionomycin
(500 ng/ml), and brefeldin A (1 ul/mL) (all reagents from Sigma-
Aldrich, St. Louis,MO) for 4 h. Cells were blocked, surface stained
(see Section Analysis of Cell Populations by FlowCytometry), and
then fixed and permeabilized using a Cytofix/Cytoperm kit (BD
Biosciences), according tomanufacturer’s instructions. Fixed cells
were washed with 1× permeablization buffer (BD Biosciences)
and stained with antibodies to IFNγ, TNFα, IL-10, IL-17, or IL-
21. Isotype matched mAbs served as negative controls to establish
background cytokine staining levels. Data were collected with BD
Accuri™ C6 software on a BD Accuri™ C6 (BD Biosciences, San
Jose, CA).
STATISTICAL ANALYSIS
Data are presented as mean ± s.e.m. Differences in cortical, stri-
atal, and total (hemispheric) infarct size data was analyzed by
Two-Way ANOVA, with one factor being brain region and the
other factor treatment group. Spleen and brain cell counts and
percentages of cellular subtypes for FACS analysis were analyzed
by Student’s t-test. Statistical significance was p < 0.05. Statistical
analyses were performed using Prism (GraphPad, La Jolla, CA).
RESULTS
RTL1000 REDUCES INFARCT VOLUME IN YOUNG AND OLDER MICE
Eight week HLA-DR2 mice exhibited a significant reduction in
infarct volume with RTL compared to vehicle (Figures 1A,B).
Representative TTC-stained cerebral sections illustrate reduction
in infarct in mice that received RTL after MCAO compared to
vehicle in young mice (Figure 1A). Cortical infarct volume was
reduced from 46.4 ± 1.7% to 28 ± 3.7% and striatal infarct vol-
ume decreased from 60.1 ± 5.9% to 34.7 ± 6.1% when mice
were given RTL following MCAO (Figure 1B). Total hemispheric
infarct volume was also significantly reduced from 31.8 ± 2.1%
to 19.1 ± 2.4% with RTL (Figure 1B). Similarly, infarct vol-
ume was significantly decreased in 16-month-old mice given RTL
compared to vehicle (Figures 1C,D). Representative TTC-stained
cerebral sections illustrate reduction in infarct in older mice
that received RTL after MCAO compared to vehicle (Figure 1C).
Cortical and striatal infarct volume went from 40.1 ± 1.6% to
20.7 ± 2.8% and 67.5 ± 3.9% to 47.7 ± 4.0% respectively, when
RTL was administered after MCAO (Figure 1D). Total hemi-
spheric infarct was also significantly reduced from 26.2 ± 1.2%
to 16.0 ± 1.3% with RTL (Figure 1D). The mortality rate of
MCAO in both treatment groups was less in young mice com-
pared to older mice while RTL reduced mortality in older mice
only (Table 1). Together, these data reveal that RTL1000 improves
stroke outcome in both young and older mice.
RTL1000 REDUCES ACTIVATED AND INFILTRATING CELLS IN THE
ISCHEMIC HEMISPHERE OF 16 MONTH BUT NOT 8-WEEK-OLD MICE
We wanted to decipher the mechanism of protection with
RTL1000 in young and older mice following MCAO by examin-
ing brain infiltrating immune and inflammatory cells. Cells were
isolated from the ischemic hemisphere 96 h after MCAO, pheno-
typed and counted (Table 2). The percent of activated microglia
and/or infiltrating monocytes/macrophages (CD11b+CD45hi) in
the ischemic hemisphere after MCAO was reduced in both 8-
week- and 16-month-old mice treated with RTL (Figure 2A).
Absolute number of activated microglia/monocytes was also sig-
nificantly reduced in the 16-month-old mice that received RTL
and there was a trend reduction in young mice that received RTL
(p = 0.068) (Figure 2B). Ischemic hemispheres of 16-month-old
mice that received RTL after MCAO also exhibited a signifi-
cant reduction in absolute CD3+ T cells and CD11c+ dendritic
cells compared to vehicle (Figures 2C,D). Young mice exhibited
a trend reduction in number of T cells in the ischemic hemi-
sphere with RTL (p = 0.064) but did not have a significantly
reduced number of dendritic cells after treatment with RTL com-
pared to vehicle (Figures 2C,D). The number of infiltrating B
cells in the ischemic hemisphere following MCAO with or with-
out RTL did not display significance difference in either young
or older mice (Figure 2E). Additionally, total infiltrating cells
and cell death were not affected by RTL treatment in either age
group (Figures 2F,G). Control (non-ischemic) hemispheres did
not exhibit an increase in inflammatory parameters (data not
shown). These data suggest that RTL1000 may reduce infarct vol-
ume following stroke using different mechanisms between young
and older mice.
SPLENIC ATROPHY IS PREVENTED WITH RTL1000
To determine other possible mechanisms of RTL1000 protec-
tion following stroke, we examined immune parameters in
the periphery. The spleen is known to have a major impact
on stroke. Our lab and others have established that splenic
atrophy occurs following stroke, releasing splenocytes into sys-
temic circulation and exacerbating neurodegeneration (Offner
et al., 2006b; Seifert et al., 2012a). Spleens were harvested
96 h after MCAO and splenocytes were counted and evalu-
ated for viability (Table 3). RTL treatment significantly inhib-
ited splenic atrophy in both 8-week- and 16-month-old mice
(Figure 3A). Splenocyte number correlated inversely with cell
death in young mice as determined by 7-AAD staining. Young
mice treated with RTL exhibited a significant decrease in
splenocyte death compared to vehicle while older mice showed
no change in 7-AAD positive cells between the treatments
(Figure 3B).
RTL1000 PRIMARILY AFFECTS PERIPHERAL IMMUNE SUBSETS IN
YOUNGER MICE
We also characterized immune cell phenotypes within the spleens
of young and oldmice, with and without RTL treatment following
MCAO (Table 4). We found a significant reduction in the fre-
quency of CD4+ T cells with RTL treatment in both young and
old mice (Figure 4A). RTL treatment also significantly reduced
the percent of CD8+ T cells, CD3+ total T cells, and CD11b+
myeloid cells in young mice only (Figures 4B–D). Furthermore,
only the Ly6C+, not Ly6G+, subset of CD11b cells were reduced
with RTL in young mice indicating that the reduction of total
CD11b cells was due to a reduction in monocytes/macrophages
not CD11b+ neutrophils (Figure 4E, Table 4). The percent of
CD19+ B cells in the spleens of young RTL treated mice following
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FIGURE 1 | RTL1000 reduces infarct volume in young and older mice.
Transient MCAO (60min) male mice were treated with 100μl vehicle or
100μg RTL1000 given S.C. at 4, 24, 48, and 72 h after MCAO. Brains were
harvested 96 h after MCAO and brain slices were stained with
2,3,5-triphenyltetrazolium chloride (TTC) (A,C). Infarct volumes were
measured as percentage of contralateral structure in young (B) and older
mice (D). ∗ Indicates p < 0.05 and ∗∗ indicates p < 0.01 compared with
vehicle group by Two-Way ANOVA.
Table 1 | Mortality and success rate of MCAO.
Animal numbers Number of animals Number of animals Number of animals Final
underwent MCAO died after MCAO excluded for SAH excluded for other reasons animal numbers
Vehicle (8 week) 13 3 (23%) 0 0 10
RTL1000 (8 week) 12 3 (25%) 0 1 (Massive cerebral hemorrhage) 8
Vehicle (16 month) 18 8 (44.4%) 2 0 8
RTL1000 (16 month) 15 5 (33.3%) 0 1 (LDF > 30%) 9
MCAO was significantly greater compared to vehicle (Figure 4F).
Collectively, in young mice RTL treatment reduces the percent of
T cells and monocytes/macrophages, both of which are known
to contribute to neurodegeneration following stroke (Campanella
et al., 2002; Yilmaz et al., 2006), while increasing potentially pro-
tective B cells (Bodhankar et al., 2014). The data also demonstrate
that RTL significantly impacts multiple subsets of splenocytes in
young mice while having much less impact on the splenocytes of
older mice after MCAO, supporting the hypothesis that RTL1000
targets different immune pathways in younger and older mice.
PERIPHERAL IMMUNE PROPERTIES CHANGE WITH AGE FOLLOWING
STROKE
In addition to the differential effects of RTL on immune subsets
after MCAO between the age groups, we also observed base-
line immunological discrepancies in the periphery of young and
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Table 2 | Ischemic (right) hemisphere.
Cell type 8-week-old mice 16-month-old mice
Vehicle RTL1000 Vehicle RTL1000
Total cell number 3.4 × 105 ±7.4 × 104 2.7 × 105 ±3.0 × 104 6.0 × 105 ±8.6 × 104# 5.4 × 105 ± 6.3 × 104#
7AAD+ 2.4 × 104 ±3451 2.0 × 104 ±2671 3.8 × 104 ±3395# 2.7 × 104 ± 3674
CD11b+ CD45hi 6.9 × 104 ±1.5 × 104 3.3 × 104 ±5135 6.4 × 104 ±8554 1.7 × 104 ± 5891**
CD3+ T cells 2769±591 1375±107 3109±624 1188± 457*
CD11c+ DC 4.1 × 104 ±9840 2.6 × 104 ±6420 2.6 × 104 ±5916 5073± 1017*#
CD19+ B cells 6149±1526 3754±734 7471±719 5679± 508
* indicates significance compare to vehicle *p ≤ 0.05; **p ≤ 0.01.
# indicates significance compared to 8-week-old mice #p ≤ 0.05.
older mice. The frequency of CD3+ total T cells and CD4+
helper T cells were significantly greater in 8-week-old vehicle and
RTL treated mice following MCAO than in 16-month-old vehicle
and RTL treated mice, respectively (Figures 4A,C). CD8+ T cells
were significantly greater in younger MCAO vehicle mice com-
pared older MCAO vehicle mice (Figure 4B). Total CD11b cells
and CD11b+Ly6C+ monocyte/macrophage subset were both
significantly higher in the spleens of young mice that received
vehicle after MCAO vs. their older counterparts (Figures 4D,E).
Additionally, the frequency of CD19+ B cells was significantly less
in the spleen following MCAO in both vehicle and RTL treated
younger mice than older mice. Innate differences in the periph-
eral immune composition between 8-week- and 16-month-old
mice followingMCAOmay give insight into the different possible
targets of RTL1000 following stroke.
SPLENIC CD4+ REGULATORY T CELLS INCREASE WITH AGE IN MCAO
MICE WHILE CD8+ REGULATORY T CELLS ARE INCREASED BY RTL1000
TREATMENT
CD4+ regulatory T cells are upregulated following stroke (Offner
et al., 2006b) and CD8+ regulatory T cells are known to suppress
CD4+ and CD8+ T cell proliferation and IFNγ production by
secreting IL-10 (Rifa’i et al., 2008). Therefore, we wanted to char-
acterize regulatory populations in the spleen to determine their
role in the periphery following stroke (Table 5). We saw no dif-
ference in CD4+ regulatory T cells (CD4+Foxp3+) in young or
older mice treated with or without RTL after stroke (Figure 5A).
However, there was a significant increase in regulatory CD4+ T
cells following MCAO in older compared to younger RTL treated
mice and the same trend (p = 0.0675) is seen with the vehicle
mice (Figure 5A). Regulatory CD8+ T cells (CD122+IL-10+)
were significantly increased in the spleens of young mice treated
with RTL after MCAO but not in older mice (Figure 5B).
T CELLS IN THE SPLEEN OF YOUNGER MICE INCREASE ACTIVATION
MARKER CD69 WHILE OLDER MICE DISPLAY ELEVATED CD44
EXPRESSION FOLLOWING MCAO
In addition to identifying the frequency of different immune sub-
sets in the spleen, functionality of those subsets following stroke
and RTL1000 treatment was also examined. CD69 is the earli-
est activation-inducible cell surface molecule and is involved in
cell signaling and lymphocyte proliferation (Serra et al., 1996).
CD44 is an adhesion receptor on T cells that is upregulated fol-
lowing initial activation and remains highly expressed on effector
and memory T cells (Baaten et al., 2012). No significant differ-
ences were seen in CD69 or CD44 expression on T cells between
vehicle and RTL treatment in either mouse group with the excep-
tion of an increase of CD44 with RTL treatment on CD4+ T cells
T cells in young mice (Figures 6A–D). There was, however, a sig-
nificant or trend increase in CD69 expression on CD4 and CD8
T cells in young mice compared to older mice (Figures 6A,B).
Furthermore, CD44 was significantly increased on splenic CD4
and CD8 T cells from older mice after MCAO compared to
younger mice (Figures 6C,D). We hypothesize that T cells in the
younger mice are able to become activated efficiently, thus the
increased CD69 expression after MCAO, yet elevated frequencies
of effector/memory T cells observed in older mice lead to a sus-
tained greater number of T cells with high CD44 expression. An
examination of migration marker and chemokine receptor CCR5
indicated no change in expression after MCAO between vehicle
and RTL treatment or age groups (Table 6).
INFLAMMATORY CYTOKINES ARE ELEVATED IN SPLEENS FROM OLDER
MICE AFTER MCAO
Inflammatory cytokines play an integral role in the effector func-
tions of the immune response. Spleen derived IFNγ directly
contributes to neurodegeneration related to stroke (Yilmaz et al.,
2006; Seifert et al., 2012b). TNFα, IL-17, and IL-21 have also have
also been linked to stroke progression (Barone et al., 1997; Li et al.,
2001; Pan and Kastin, 2007; Gelderblom et al., 2012; Swardfager
et al., 2013; Clarkson et al., 2014). We found no significance dif-
ference in the frequency of specific immune cells secreting IFNγ,
TNFα, IL-17, or IL-21 between vehicle and RTL treated mice
with either young or old MCAO mice (Table 7). IL-21 produc-
tion by splenic CD4+ T cells was significantly greater in older
mice compared to younger mice following MCAO for the RTL
treated group only and there was no difference in IL-17 produc-
tion between the two age groups with either vehicle or treatment
(Table 7). IFNγ producing CD4+ and CD8+ T cells were sig-
nificantly greater in the spleens of older mice than younger
mice following MCAO (Figures 7A,C,D). Similarly, TNFα posi-
tive CD4+ and CD11b+ cells were also increased in the spleens
of oldermice than youngermice (Figures 7B,E,F).We believe that
96 h post-MCAO may be a window of time where memory and
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FIGURE 2 | RTL1000 reduces activated and infiltrating cells in the
ischemic hemisphere of 16 month but not 8-week-old mice. Brains from
young or older male mice were harvested 96 h after MCAO. Leukocytes were
isolated from the ischemic hemisphere and phenotyped by flow cytometry.
Representative flow cytometry dot plots of activated microglia/monocytes
(A). Absolute number of each cell phenotype was calculated using
phenotype percent and total cell numbers. CD11b+CD45hi activated
microglia/monocytes (B), CD3+ T cells (C), CD11c+ dendritic cells (D) and
CD19+ B cells (E) in the ischemic hemisphere were determined. Total cell
number was calculated by multiplying cells per microliter run through the
flow cytometer by the total sample volume (F). Cells were analyzed for death
by 7-AAD (G). Values represent mean numbers (±s.e.m.) of indicated cell
subsets from 5 to 6 young mice per treatment group, from 2 to 3 separate
experiments and 4 older mice per group, from 2 separate experiments
each. ∗ Indicates p < 0.05 and ∗∗ indicates p < 0.01 compared with vehicle
group by t-test.
effector immune cells which are quick to reactivate have accu-
mulated in older mice, thus leading to immediate and amplified
cytokine production compared to the higher frequency of naïve
cells in young mice.
DISCUSSION
In the next few decades nearly 4% of the population will be
affected by stroke (Ovbiagele et al., 2013) leading to increase in
stroke-related mortality and disability and an even greater need
for stroke therapies. Furthermore, understanding how the body
responds to stroke as we age is equally as imperative. Previous
work done by our lab and others has outlined the contribut-
ing immunological factors that influence neurodegeneration fol-
lowing stroke. In young male mice, MCAO induces peripheral
immune pro-inflammatory activation that triggers immune cell
efflux from the spleen into circulation, some of which go on
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Table 3 | Splenocyte number and viability.
8-week-old mice 16-month-old mice
Vehicle RTL1000 Vehicle RTL1000
Splenocyte number 1.9 × 107 ±5.5 × 106 4.2 × 107 ±5.6 × 106* 2.6 × 107 ±3.8 × 106 4.2 × 107 ± 4.1 × 106**
Cell death % 11.3±0.8 5.3±1.36** 9.2±1.28 9.2± 1.63
* indicates significance compare to vehicle *p ≤ 0.05 **p ≤ 0.01.
FIGURE 3 | Splenic atrophy is prevented with RTL1000. Spleens were
harvested 96 h after MCAO. Splenocytes were isolated and counted by a
Cellometer T4 and total splenocyte number was calculated (A). Values
represent mean numbers (±s.e.m.) of 6 young vehicle, 5 young RTL, 12
older vehicle, and 13 older RTL mice. Splenocyte death was determined by
7-AAD fluorescence (B). Values represent mean numbers (±s.e.m.) of 5
young mice from each treatment group, 6 older vehicle and 9 older RTL
mice. ∗ Indicates p < 0.05 and ∗∗ indicates p < 0.01 compared with vehicle
group by t-test.
Table 4 | Cell types in the spleen.
8-week-old mice 16-month-old mice
Cell type Vehicle RTL1000 Vehicle RTL1000
Total CD3+ T cells 34.2±1.6 27.7± 1.8* 21.0±2.1## 18.4±0.7###
CD4+ T cells 18.7±1.2 15.1± 0.6* 12.8±0.8## 9.8±0.3**###
CD8+ T cells 13.9±0.9 9.9± 1.2* 10.0±1.0# 10.0±0.9
CD11b+ myeloid cells 4.9±0.4 3.6± 0.4* 3.2±0.2## 3.5±0.2
CD11b+Ly6G+ neutrophils 4.9±0.4 3.8± 0.5 4.7±0.3 4.3±0.3
CD11b+Ly6C+ monocytes 3.5±0.3 2.2± 0.4* 2.6±0.3# 2.9±0.2
CD11c+ dendritic cells 1.6±0.1 1.8± 0.2 1.3±0.1 1.9±0.2
CD19+ B cells 42.8±2.7 53.7± 2.0* 59.0±1.5## 62.3±1.5##
* indicates significance compare to vehicle *p ≤ 0.05; **p ≤ 0.01.
# indicates significance compared to 8-week-old mice #p ≤ 0.05; ##p ≤ 0.01;
###p ≤ 0.001.
to target the brain (Offner et al., 2006a,b; Seifert et al., 2012a).
Despite the over 1000 neuroprotectants that have been successful
in preclinical studies and more than 100 clinical trials initiated,
there has been an astounding failure in translation of those neu-
roprotectants to successful stroke therapies in humans (Turner
FIGURE 4 | The effect of RTL1000 on peripheral immune subsets in
younger vs. older mice. Spleens were harvested 96 h after MCAO and
immunophenotyped by flow cytometry. The frequency of CD4+ T cells (A),
CD8+ T cells (B), CD3+ T cells (C), CD11b+ monocytes/neutrophils (D),
CD11b+Ly6C+ monocytes/macrophages (E), and CD19+ B cells (F)were
determined. Values representmean numbers (±s.e.m.) of 5 youngmice from
each treatment group, 4–6 older vehicle and 9 older RTL mice. ∗ Indicates
p < 0.05, ∗∗ indicates p < 0.01, and ∗∗∗ indicates p < 0.001 compared with
vehicle group by t-test.
et al., 2013). One contributing factor to the lack of success in
clinical stroke therapy is the underrepresentation of older mice
in therapy based research to more accurately represent the age of
most humans afflicted by stroke.
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Table 5 | Regulatory cells in the spleen.
Cell type 8-week-old mice 16-month-old mice
Vehicle RTL1000 Vehicle RTL1000
CD4+Foxp3+ 15.42±2.0 16.12±0.8 21.63±2.0 20.2±1.4#
CD8+CD122+ IL-10+ 3.9±0.4 5.2±0.4* 4.2±0.2 3.4±0.8
* indicates significance compare to vehicle *p ≤ 0.05.
# indicates significance compared to 8-week-old mice #p ≤ 0.05.
FIGURE 5 | Splenic CD4+ regulatory T cells increase with age in
MCAO mice while CD8+ regulatory T cells are increased by
RTL1000 treatment. Spleens were harvested 96 h after MCAO and
immunophenotyped by flow cytometry. CD4+ regulatory T cells were
gated on CD4+ positive splenocytes and determined by Foxp3
expression compared to isotype (A). Values represent mean numbers
(±s.e.m.) of 5 young mice from each treatment group, 4 older vehicle
and 7 older RTL mice. CD8+ regulatory T cells were gated on the
CD8+CD122+ subset and determined by IL-10 expression compared to
isotype (B). Values represent mean numbers (±s.e.m.) of 5 young mice
from each treatment group, 3 older vehicle and 5 older RTL mice.
∗ indicates p < 0.05.
RTL therapy has been shown by our lab to be a promising
neuroprotectant therapy for stroke in young male mice (Akiyoshi
et al., 2011; Dziennis et al., 2011). Here we report that RTL1000
similarly reduced infarct volume in older and younger HLA-DR2
male mice when administered after the onset of MCAO. RTL1000
also reduced the mortality rate of MCAO in older mice. Cerebral
ischemia induces activation of resident microglia and an influx of
peripheral leukocytes into the brain (Huang et al., 2006). In older
mice, RTL treatment significantly reduced the absolute number of
activated monocytes/microglia, T cells, and dendritic cells in the
ischemic hemisphere following MCAO. Although these cell num-
bers were also reduced with RTL in young mice after MCAO, the
differences remained insignificant. RTL did not affect ischemic
total infiltrating cell number or cell death, yet both were greater
in older mice compared to younger mice after MCAO indicating
possible differences in how young and older individuals respond
to stroke.
FIGURE 6 | T cells in the spleen of younger mice increase activation
marker CD69 while older mice display elevated CD44 expression
following MCAO. Spleens were harvested 96 h after MCAO. Early T cell
activation was determined by gating on CD4+ (A) or CD8+ (B) subsets and
measuring expression of early activation marker, CD69. Effector/central
memory was determined by gating on CD4+ (C) or CD8+ (D) subsets and
measuring expression of CD44. Values represent mean numbers (±s.e.m.)
of 5 young mice from each treatment group, 7 older vehicle and 9 older RTL
mice. ∗ indicates p < 0.05 and ∗∗∗ indicates p < 0.001 compared with
vehicle group by t-test.
The peripheral inflammatory response to stroke has been
extensively studied and can give crucial insight into the mecha-
nisms of neuroprotection of stroke therapy. One of the hallmarks
of the immune response to stroke is splenic atrophy (Offner et al.,
2006b). RTL1000 therapy restored total splenocyte numbers in
young and oldermice afterMCAO compared to vehicle indicating
a therapy based prevention of splenic atrophy in both age groups.
There is an inverse correlation of percent cell death and total cell
number in the spleen of young mice. The same trend of increased
splenocyte death following MCAO was also observed in young
male C57BL/6 mice by our lab (Offner et al., 2006b). RTL therapy
did not, however, reduce splenocyte death in older mice com-
pared to vehicle. These data suggest that RTL therapy prevents
splenic atrophy by preventing cell death and likely by inhibit-
ing splenocyte migration in young mice while only preventing
splenocyte migration in older mice.
Previous work published by our lab revealed that in addi-
tion to a total reduction of cell numbers in the spleen, MCAO
also contributes to a shift in the frequencies of the different
immune subsets that comprise the spleen (Offner et al., 2006b).
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Table 6 | Activation/migration markers on T cells.
Cell type/Marker 8-week-old mice 16-month-old mice
Vehicle RTL1000 Vehicle RTL1000
CD4+CD69+ 12.7±1.1 12.3±0.4 2.4±0.4### 1.8±0.1###
CD8+CD69+ 4.1±0.6 3.2±0.2 2.4±0.6 1.4±0.1###
CD4+CD44+ 25.5±0.8 30.1±1.5* 41.5±1.7### 43.3±1.9###
CD8+CD44+ 22.3±1.3 25.1±1.3 48.5±1.7### 51.0±3.0###
CD3+CCR5+ 8.5±1.3 9.3±0.4 8.6±1.3 8.4±0.4
* indicates significance compare to vehicle *p ≤ 0.05.
# indicates significance compared to 8-week-old mice ###p ≤ 0.001.
Table 7 | Cytokine production.
Cell type/Cytokine 8-week-old mice 16-month-old mice
Vehicle RTL1000 Vehicle RTL1000
CD4+IFNγ+ 4.8±0.7 5.6±0.3 10.2±1.7# 9.5±1.6#
CD8+IFNγ+ 6.0±1.2 7.0±0.4 21.7±1.5### 22.1±5.1#
CD4+TNFα+ 7.2±2.1 6.9±1.4 30.7±1.9### 33.1±3.2###
CD11b+TNFα+ 7.0±0.6 7.1±0.5 33.1±2.6### 39.4±1.4###
CD4+IL-17+ 1.3±0.1 1.8±0.2 1.6±0.6 1.7±0.4
CD4+IL-21+ 1.8±0.3 1.6±0.2 3.5±1.2 3.0±0.5#
# indicates significance compared to 8-week-old mice #p ≤ 0.05; ###p ≤ 0.001.
Specifically, we saw a significant increase in CD4+, CD8+, and
CD3+ T cells and a significant decrease of B cells in the spleens
of C57BL/6 mice 96 h after MCAO compared to sham (Offner
et al., 2006b). RTL treatment significantly decreased the fre-
quency of CD4+, CD8+, and CD3+ T cells and increased B cells
in the spleen of young mice following MCAO suggesting that
in young mice, RTL treatment counteracts changes in immune
cell subsets that occur in the spleen after stroke. In addition
to stroke induced changes in T and B cell frequencies in the
spleen, RTL treatment led to a modest but significant reduction
in monocytes/macrophages in young mice. Circulating mono-
cytes and macrophages are recruited to the ischemic brain 3–7
days after stroke where they contribute to neurodegeneration and
recruitment of additional pathogenic immune cells (Chiba and
Umegaki, 2013). Since we do not observe a recruitment of acti-
vated monocytes/macrophages into the ischemic brain of RTL
treated young mice after MCAO, we can hypothesize that the
reduction of monocytes/macrophages in the spleen is due to
inhibition of activation-induced cell expansion and not cellular
migration out of the spleen.
The changes in splenocyte subsets between RTL treated and
vehicle control mice were not the only remarkable differences
observed in the spleen 96 h after MCAO. In fact, of the six
immune subsets that were significantly affected by RTL treat-
ment after MCAO in young mice, CD4+ T cells were the only cell
group that were also significantly reduced with older, RTL treated
MCAOmice compared to vehicle. Additionally, major differences
were observed in peripheral immune cell frequencies after stroke
in young vs. older control mice. CD4+, CD8+, and CD3+ T cells,
total CD11b+ and CD11b+Ly6C+ monocytes/macrophages
were all significantly reduced in the older control MCAO mice
compared to the young control mice. RTL treated groups followed
the same pattern for CD4+ and CD3+ T cells. CD19+ B cells
were significantly elevated in both the control and RTL groups
of older mice following MCAO compared to young mice. Such
notable disparities in peripheral immune frequencies continue
to confirm that younger and older mice respond to stroke and
RTL treatment following stroke through different immunological
mechanisms.
The frequency of CD4+ Foxp3+ regulatory cells in the spleen
increases after MCAO (Offner et al., 2006b) although there are
contradicting data on whether CD4+ regulatory T cells dimin-
ish or exacerbate stroke related neuronal damage (Schabitz, 2013;
Xu et al., 2013). Recent studies have reported that CD4+ Tregs
play a protective role against damage following stroke (Liesz et al.,
2009; Planas and Chamorro, 2009; Li et al., 2013), while others
demonstrate Tregs as harmful promoters of neurodegeneration
(Kleinschnitz et al., 2013a; Kleinschnitz and Wiendl, 2013b) or
find that Tregs do not influence stroke (Ren et al., 2011; Gu et al.,
2012; Stubbe et al., 2013). The conflicting reports of CD4+ Tregs
and stroke thus far indicate that there is still much unknown
about the regulation of the immune response after stroke and
even less known about Treg response to stroke in older subjects. In
our study RTL did not affect the frequency of CD4+Foxp3+Tregs
in either older or younger mice. There was, however, a trending
increase (p = 0.0675) in Tregs in older vehicle vs. younger vehi-
cle mice and a significant increase in RTL treated mice compared
to younger RTL mice. The increase in spleen derived Tregs after
MCAO in older mice agrees with multiple reports of Treg increase
with age contributing to immune senescence (Sharma et al., 2006;
Rosenkranz et al., 2007; Lages et al., 2008; Williams-Bey et al.,
2011; Raynor et al., 2012). There are far fewer reports on the
effect of regulatory CD8+ T cells during and after stroke. CD8+
Tregs co-express CD122 and kill/suppress effector cells via per-
forin and immunosuppressive cytokines, such as IL-10 (Wang and
Alexander, 2009). IL-10 producing CD8+CD122+ Tregs have
been directly correlated with a decrease in infarct after MCAO
(Banerjee et al., 2013; Bodhankar et al., 2013). CD8+CD122+IL-
10+ cells were significantly greater in the periphery of young RTL
treated mice but not older RTL treated mice compared to their
vehicle counterparts. Although infarct sizes were significantly less
with RTL treatment of both age groups, only older mice had a sig-
nificant reduction in activated microglia/monocytes, T cells, and
dendritic cells compared to vehicle. We speculate that CD8+ reg-
ulatory cells from the periphery of RTL treated older mice had
already migrated to the brain, thus reducing activated immune
cells in the ischemic hemisphere, while remaining in the spleen of
younger RTL treated mice.
CD69 is the earliest inducible cell surface antigen expressed
with T cell activation. Although we observed no change in CD69
expression in mice that received RTL treatment after MCAO,
there were significantly less CD69+ T cells from older mice after
MCAO. In humans, aged subjects have a lower proportion of
recently activated CD69+ T cells compared to younger controls
and fail to upregulate CD69 expression following stimulation
through CD3, PHA or PMA/Ionomycin as effectively as younger
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FIGURE 7 | Inflammatory cytokines are elevated in spleens from older
mice after MCAO. Spleens were harvested 96 h after MCAO. Representative
flow cytometry dot plots of IFNγ (A) and TNFα (B) producing immune
subsets. IFNγ production was determined by gating on CD4+ (C) or CD8+
(D) subsets and measuring IFNγ positive cells compared to isotype. TNFα
production was determined by gating on CD4+ (E) or CD11b+ (F) subsets
and measuring TNFα positive cells compared to isotype. Values represent
mean numbers (±s.e.m.) of 5 young mice from each treatment group, 3 older
vehicle and 5 older RTL mice. ∗ Indicates p < 0.05 and ∗∗∗ indicates
p < 0.001 compared with vehicle group by t-test.
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controls (Serra et al., 1996; Schindowski et al., 2002). Therefore,
the discrepancy in CD69 expression between older and younger
mice can be attributed to age related immune senescence in T
cell activation. CD44 is a widely expressed adhesion receptor that
becomes upregulated and maintained on T cells after antigen spe-
cific activation. CD44 is commonly associated with the effector
memory and central memory T cell populations and has numer-
ous functions. We were surprised to see an elevated level of CD44
on CD4+ T cells from younger mice that had received RTL treat-
ment after MCAO. Although commonly known for its role in
promoting the immune response, cell migration and T cell prolif-
eration, CD44 is also involved in various regulatory mechanisms
such as maintaining functional Tregs and cell survival (Baaten
et al., 2010). CD44 has also been shown to be involved in limit-
ing and resolving inflammation (Johnson and Ruffell, 2009). We
speculate the increase in CD44 on CD4+ T cells from younger
mice that received RTL after MCAO could be linked to a reg-
ulatory role that assisted in the decrease of neuroinflammation
and splenic atrophy. The percent of CD44+ and memory T cells
increases with age (Barrat et al., 1995; Naylor et al., 2005); there-
fore the significantly greater CD44 expressing CD4 and CD8 T
cells in the spleen of older vehicle or RTL treated mice after
MCAO is likely indicative of a larger effector and central memory
population.
Inflammatory cytokines are well-known to play a destructive
role in brain inflammation following stroke. Spleen derived IFNγ
is directly linked to neurodegeneration (Seifert et al., 2012b) and
TNFα promotes inflammation and leukocyte infiltration into the
brain, thus increasing infarct size (Feuerstein et al., 1994; Barone
et al., 1997). The neuroprotection observed with RTL therapy
in both young and older mice cannot be attributed to a change
in peripheral cytokine secretion as demonstrated in Figure 7.
Interestingly, with both treatment and vehicle, IFNγ or TNFα
production by CD4+ and CD8+ T cells or CD4+ T cells and
CD11b+ macrophages, respectively, was significantly greater in
older mice compared to young mice after MCAO. Both IFNγ
and TNFα production increase with age in CD4+/CD8+ T cells
and mononuclear cells, respectively (Fagiolo et al., 1993; Bandres
et al., 2000; Yen et al., 2000). The abundant amount of mem-
ory cells in older compared to younger individuals, which we
also observed, requires less secondary stimulus for activation and
cytokine secretion and is hypothesized to be partially responsi-
ble for the cytokine elevation with age. Although the increase in
IFNγ and TNFα in the older mice did not lead to an increase of
infarct size compared with young mice, there were significantly
greater total cells and cell death in the ischemic hemisphere of
16-month-old mice.
To summarize, the current study demonstrates that treatment
with RTL1000 following MCAO significantly reduces infarct vol-
ume in 16-month-old mice similar to 8-week-old mice. However,
the mechanism of neuroprotection is different between older and
younger mice. RTL1000 significantly reduced infiltrating leuko-
cytes in the brain of older mice while significantly reducing cell
death and altering the frequency of specific splenocyte subsets
in young mice. RTL1000 also inhibited splenic atrophy in both
age groups. Additionally, there were major differences in spleno-
cyte activation and cytokine secretion between younger and older
mice in response to stroke. In conclusion, age-specific differences
in the immune response to stroke resulted in RTL protection from
experimental stroke through peripheral-based immune regula-
tion in young mice and inflammatory tissue-specific protection
of older mice.
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